Biofrontera Inc. (BFRI): M&A transaction — Biofrontera sells Xepi® license to Pelthos for up to $10M; receives $3M at close

Biofrontera Inc.

Sold US license of Xepi® (ozenoxacin) cream to Pelthos Therapeutics for up to $10M total consideration.
Received $3M cash at closing; additional $1M due upon availability of commercial product.
Up to $6M in milestones: $3M each upon achieving $10M and $15M annual net sales of Xepi®.
Company expects proceeds to fund operations to profitability, supporting Ameluz® PDT franchise.
Transaction bolsters cash position after recent restructuring of agreement with Biofrontera AG.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Biofrontera Inc. completed a disposition involving Pelthos Therapeutics Inc. for maximum of $10,000,000 (closed 2025-11-06).

Action: disposition
Counterparty: Pelthos Therapeutics Inc.
Consideration: maximum of $10,000,000
Closing: 2025-11-06

Exact text from the filing

Capitalized terms used below that are not defined herein shall have the meanings ascribed to such terms in the APA. The purchase price for the Acquired Assets is a maximum of $10,000,000, payable as follows: 1) $3,000,000 in cash, paid on the Closing Date; 2) Subject to availability of certain commercial quantities of the Product and other terms and conditions of

View on SEC.gov

Browse all m&a transactions →

Biofrontera Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-021189

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.